» Articles » PMID: 34103482

Catalpol Ameliorates Depressive-like Behaviors in CUMS Mice Via Oxidative Stress-mediated NLRP3 Inflammasome and Neuroinflammation

Overview
Date 2021 Jun 9
PMID 34103482
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of the present study was to investigate whether catalpol exhibited neuroprotective effects in chronic unpredictable mild stress (CUMS) mice through oxidative stress-mediated nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin-domain-containing 3 (NLRP3) inflammasome and neuroinflammation. Deficits in behavioral tests, including open field test (OFT), forced swim test (FST), and elevated plus-maze test (EPM), were ameliorated following catalpol administration. To study the potential mechanism, western blots, quantitative real-time PCR (qRT-PCR) analysis and immunofluorescence imaging were performed on the hippocampus samples. We found that the defects of behavioral tests induced by CUMS could be reversed by the absence of NLRP3 and NLRP3 inflammasome might be involved in the antidepressant effects of catalpol on CUMS mice. Similar to the NLRP3 inflammasome, the expression of interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), and inducible nitride oxide synthase (iNOS) were increased after CUMS. The current study demonstrated that catalpol possessed anti-inflammatory effect on CUMS mice and inhibited microglial polarization to the M1 phenotype. In addition, the activity of mitochondrial oxidative stress might be involved in the NLRP3 activation, which was proved by the downregulation of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved IL-1β, after the administration of mitochondrion-targeted antioxidant peptide SS31. Taken together, we provided evidence that catalpol exhibited antidepressive effects on CUMS mice possibly via the oxidative stress-mediated regulation of NLRP3 and neuroinflammation.

Citing Articles

Chronic unpredictable mild stress induces anxiety-like behavior in female C57BL/6N mice, accompanied by alterations in inflammation and the kynurenine pathway of tryptophan metabolism.

Luo Y, Jiang N, Zhang Y, Zhao Y, Chen F, Li X Front Neurosci. 2025; 19:1556744.

PMID: 40078708 PMC: 11897007. DOI: 10.3389/fnins.2025.1556744.


Exercise-induced Activation of SIRT1/BDNF/mTORC1 Signaling Pathway: A Novel Mechanism to Reduce Neuroinflammation and Improve Post-stroke Depression.

Tang J, Lu L, Yuan J, Feng L Actas Esp Psiquiatr. 2025; 53(2):366-378.

PMID: 40071363 PMC: 11898262. DOI: 10.62641/aep.v53i2.1838.


Ferroptosis, pathogenesis and therapy in AS co-depression disease.

Zhao Y, Ren P, Luo Q, Li X, Cheng X, Wen Y Front Pharmacol. 2025; 16:1516601.

PMID: 40066336 PMC: 11891183. DOI: 10.3389/fphar.2025.1516601.


Antioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment.

Aleksandrova Y, Neganova M Antioxidants (Basel). 2025; 14(2).

PMID: 40002385 PMC: 11851806. DOI: 10.3390/antiox14020199.


Therapeutic potential of rutin in premenstrual depression: evidence from and studies.

Wang X, Xia X, Song X, Zhou Y, Ma M, Ren Y Front Pharmacol. 2025; 15:1525753.

PMID: 39877393 PMC: 11772486. DOI: 10.3389/fphar.2024.1525753.


References
1.
Stahl S . Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1999; 51(3):215-35. DOI: 10.1016/s0165-0327(98)00221-3. View

2.
Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J . Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Med. 2018; 16(1):36. PMC: 5842559. DOI: 10.1186/s12916-018-1022-x. View

3.
Wyska E . Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opin Drug Metab Toxicol. 2019; 15(10):831-847. DOI: 10.1080/17425255.2019.1669560. View

4.
Shieh J, Cheng K, Chung H, Kerh Y, Yeh C, Cheng J . Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocin-induced diabetic rats. J Agric Food Chem. 2011; 59(8):3747-53. DOI: 10.1021/jf200069t. View

5.
Jiang B, Shen R, Bi J, Tian X, Hinchliffe T, Xia Y . Catalpol: a potential therapeutic for neurodegenerative diseases. Curr Med Chem. 2015; 22(10):1278-91. DOI: 10.2174/0929867322666150114151720. View